Cargando…

Hot topics from the Assemblies

Summary: Eosinophilic chronic obstructive pulmonary disease (COPD) is characterised by a peripheral blood differential eosinophil count of 2% or more. This phenotype is found in roughly 40% of patients with COPD. These patients have an increased frequency of exacerbations, but benefit from inhaled g...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980479/
https://www.ncbi.nlm.nih.gov/pubmed/29875836
http://dx.doi.org/10.1183/20734735.142118
_version_ 1783327890675335168
collection PubMed
description Summary: Eosinophilic chronic obstructive pulmonary disease (COPD) is characterised by a peripheral blood differential eosinophil count of 2% or more. This phenotype is found in roughly 40% of patients with COPD. These patients have an increased frequency of exacerbations, but benefit from inhaled glucocorticoids as part of a triple therapy regime. However, 30–40% of these patients continue to have significant exacerbations, meaning targeted therapy to reduce eosinophil counts could play a role in future therapy. Mepolizumab blocks interleukin-5 and has been associated with a decreased rate of exacerbation in eosinophilic asthma.
format Online
Article
Text
id pubmed-5980479
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-59804792018-06-07 Hot topics from the Assemblies Breathe (Sheff) Expert opinion Summary: Eosinophilic chronic obstructive pulmonary disease (COPD) is characterised by a peripheral blood differential eosinophil count of 2% or more. This phenotype is found in roughly 40% of patients with COPD. These patients have an increased frequency of exacerbations, but benefit from inhaled glucocorticoids as part of a triple therapy regime. However, 30–40% of these patients continue to have significant exacerbations, meaning targeted therapy to reduce eosinophil counts could play a role in future therapy. Mepolizumab blocks interleukin-5 and has been associated with a decreased rate of exacerbation in eosinophilic asthma. European Respiratory Society 2018-06 /pmc/articles/PMC5980479/ /pubmed/29875836 http://dx.doi.org/10.1183/20734735.142118 Text en Copyright ©ERS 2018 http://creativecommons.org/licenses/by-nc/4.0/ Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0 (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Expert opinion
Hot topics from the Assemblies
title Hot topics from the Assemblies
title_full Hot topics from the Assemblies
title_fullStr Hot topics from the Assemblies
title_full_unstemmed Hot topics from the Assemblies
title_short Hot topics from the Assemblies
title_sort hot topics from the assemblies
topic Expert opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980479/
https://www.ncbi.nlm.nih.gov/pubmed/29875836
http://dx.doi.org/10.1183/20734735.142118